REVA Medical Inc. Announces Interim Clinical Results at EuroPCR

SAN DIEGO, May 21, 2012 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company"), announced at the European Course on Revascularization, the largest European stent meeting held last week in Paris, France, that there were no reported Major Adverse Coronary Events (MACE) on 16 patients who were enrolled in the Company's RESTORE trial, with no incidences of ischemic target lesion revascularization (TLR), myocardial infarction (heart attack) or stent thrombosis. The first enrolled case is approaching 5 months and all patients enrolled in the study continue to do well.